Who owns STRO?
Institutional ownership of Sutro Biopharma Inc. from Form 13F, Q2 2026
97 institutional managers reported holding Sutro Biopharma Inc. (STRO) in Form 13F filings for Q2 2026, with 16,480,061 shares worth $546M. The largest reported holder was Perceptive Advisors LLC. Managers that filed both quarters added a net 2,362,389 shares (+16.7%). 41 opened new positions and 14 sold out.
- Funds holding
- 97
- Value held
- $546M
- New / sold out
- 41 / 14
- Net shares, same filers
- +16.7%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of STRO
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| Perceptive Advisors LLC | $43.3M | 7.9% | 1,304,846 | Added |
| BVF Inc | $41.6M | 7.6% | 1,251,788 | Unchanged |
| Affinity Asset Advisors, LLC | $38.9M | 7.1% | 1,172,487 | Added |
| BlackRock, Inc. | $37.3M | 6.8% | 1,122,655 | Added |
| Samsara Biocapital, LLC | $35.3M | 6.4% | 1,062,872 | Unchanged |
| Kynam Capital Management, LP | $29.0M | 5.3% | 872,558 | Unchanged |
| Orbimed Advisors LLC | $24.7M | 4.5% | 743,944 | Trimmed |
| Balyasny Asset Management L.P. | $23.6M | 4.3% | 711,162 | Added |
| Vanguard Capital Management LLC | $23.0M | 4.2% | 694,219 | Trimmed |
| Eventide Asset Management, LLC | $19.4M | 3.6% | 585,262 | Trimmed |
| Velan Capital Investment Management LP | $17.0M | 3.1% | 512,160 | Unchanged |
| Woodline Partners LP | $15.2M | 2.8% | 458,029 | Added |
| ADAR1 Capital Management, LLC | $13.4M | 2.5% | 404,014 | Trimmed |
| Geode Capital Management, LLC | $12.9M | 2.4% | 389,692 | Added |
| Acadian Asset Management LLC | $12.4M | 2.3% | 373,839 | Added |
| Millennium Management LLC | $12.2M | 2.2% | 365,972 | Added |
| State Street Corp | $10.2M | 1.9% | 305,979 | Added |
| Merck & Co., Inc. | $9.0M | 1.7% | 272,351 | New |
| Acuta Capital Partners, LLC | $9.0M | 1.6% | 270,251 | Added |
| Ameriprise Financial Inc | $8.1M | 1.5% | 244,669 | New |
| Point72 Asset Management, L.P. | $7.9M | 1.4% | 237,827 | Trimmed |
| KVP Capital Advisors, LP | $7.5M | 1.4% | 226,575 | Unchanged |
| UBS Group AG | $6.9M | 1.3% | 208,512 | Trimmed |
| Two Sigma Investments, LP | $6.7M | 1.2% | 201,688 | Added |
| Vanguard Portfolio Management LLC | $6.6M | 1.2% | 197,562 | New |
Share of 13F holdings is each fund's shares as a share of the 16,480,061 STRO shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- BlackRock, Inc. Added+$29.5M
- Perceptive Advisors LLC Added+$19.6M
- Merck & Co., Inc. New+$9.0M
- State Street Corp Added+$8.4M
- Balyasny Asset Management L.P. Added+$8.1M
- Ameriprise Financial Inc New+$8.1M
- Geode Capital Management, LLC Added+$7.2M
- Vanguard Portfolio Management LLC New+$6.6M
- Nuveen, LLC New+$5.6M
- JPMorgan Chase & Co New+$5.3M
Biggest sellers in Q2 2026
- Ra Capital Management, L.p. Sold out-$17.8M
- Point72 Asset Management, L.P. Trimmed-$15.1M
- UBS Group AG Trimmed-$6.1M
- Adage Capital Partners GP, L.l.c. Sold out-$5.0M
- Opaleye Management Inc. Sold out-$4.7M
- Eventide Asset Management, LLC Trimmed-$4.3M
- ADAR1 Capital Management, LLC Trimmed-$4.0M
- Susquehanna International Group, LLP Trimmed-$2.5M
- Orbimed Advisors LLC Trimmed-$1.9M
- Eversept Partners, LP Sold out-$1.8M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $162M and sold $73.0M; 24 added and 18 trimmed.
Schedule 13D and 13G filings on STRO
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-07-30BlackRock, Inc. SCHEDULE 13G filed by BlackRock Inc.Schedule 13G
- 2026-05-15Samsara BioCapital, L.P. SCHEDULE 13G filed by Sutro Biopharma Inc.Schedule 13G
- 2026-04-21PERCEPTIVE ADVISORS LLC SCHEDULE 13G filed by Sutro Biopharma Inc.Schedule 13G
- 2026-02-19BIOTECHNOLOGY VALUE FUND L P SCHEDULE 13G filed by Sutro Biopharma Inc.Schedule 13G
- 2025-10-23Affinity Asset Advisors, LLC SCHEDULE 13G filed by Sutro Biopharma Inc.Schedule 13G
- 2025-06-30MILLENNIUM MANAGEMENT LLC SCHEDULE 13G filed by Sutro Biopharma Inc.Schedule 13G
- 2025-04-04RA CAPITAL MANAGEMENT, L.P. SCHEDULE 13G filed by Sutro Biopharma Inc.Schedule 13G
Questions about STRO ownership
- Who owns STRO stock?
- 97 institutional investment managers reported STRO positions in their Form 13F filings for Q2 2026, holding 16,480,061 shares worth $546M in total. Perceptive Advisors LLC reported the largest position.
- Are funds buying or selling STRO?
- In Q2 2026, 41 managers opened new STRO positions, 24 added, 18 trimmed and 14 sold out. Managers that filed in both quarters added a net 2,362,389 shares.
- How current is this STRO institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to STRO by CUSIP. Options are left out. STRO news and filings · STRO insider trades · Top funds